Common Contracts
3 similar License Agreement contracts by Elixir Pharmaceuticals, Inc.
EX-10.38 3 dex1038.htm LICENSE AGREEMENT WITH BRISTOL-MYERS SQUIBB COMPANY WHENEVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE DENOTED BY AN ASTERISK *), SUCH CONFIDENTIAL INFORMATION HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES...License Agreement • May 5th, 2020 • New York
THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into as of April 25, 2005, by and between Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”), and Elixir Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at One Kendall Square, Building 1000, Fifth Floor, Cambridge, Massachusetts 02139 (“Elixir”). BMS and Elixir are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENT between ELIXIR PHARMACEUTICALS, INC. and BRISTOL-MYERS SQUIBB COMPANYLicense Agreement • January 7th, 2008 • Elixir Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into as of April 25, 2005, by and between Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”), and Elixir Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at One Kendall Square, Building 1000, Fifth Floor, Cambridge, Massachusetts 02139 (“Elixir”). BMS and Elixir are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENT between ELIXIR PHARMACEUTICALS, INC. and BRISTOL-MYERS SQUIBB COMPANYLicense Agreement • November 1st, 2007 • Elixir Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into as of April 25, 2005, by and between Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”), and Elixir Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at One Kendall Square, Building 1000, Fifth Floor, Cambridge, Massachusetts 02139 (“Elixir”). BMS and Elixir are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
